5 completed. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 5 |
Follow Hepatitis C Infection: new trials by email Literature Review of Hepatitis C Infection trials Research Report on Hepatitis C Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults ombitasvir/paritaprevir/ritonavir, dasabuvir - Hepatitis C Infection, Hepatitis C Virus | Phase 3 | Completed | AbbVie | 166 | 2015-11-24 | 2021-07-30 |
| Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt 2 DAA, RBV - HCV, Hepatitis C Infection | Phase 3 | Completed | AbbVie | 160 | 2014-11-04 | 2021-07-30 |
| Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068) Grazoprevir + Elbasvir, Ribavirin - Hepatitis C Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 420 | 2014-06-05 | 2021-02-05 |
| Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients. Civacir® 10% - Hepatitis C Infection, Viruses | Phase 3 | Completed | Biotest Pharmaceuticals Corporation | 80 | 2013-06-01 | 2017-03-15 |
| An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users hepatitis B vaccine 3 dose schedule (0,1,2 month), HBV Vaccination Self-Efficacy Intervention - Hepatitis B Infection, Hepatitis C Infection | Phase 3 | Completed | National Institute on Drug Abuse (NIDA) | 1260 | 2004-01-01 | 2017-01-11 |
Hepatitis C (5) · Carcinoma, Hepatocellular (1) · Fibrosis (1) · HIV Infections (1) · Hepatitis B (1) · Hepatitis, Viral, Human (1) · Liver Cirrhosis (1) · Virus Diseases (1)
Blood-Borne Infections (5) · Communicable Diseases (5) · Digestive System Diseases (5) · Flaviviridae Infections (5) · Hepatitis (5) · Infections (5) · Liver Diseases (5) · RNA Virus Infections (5) · Hepatitis, Viral, Human (4) · Virus Diseases (4) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Adenocarcinoma (1) · Carcinoma (1) · DNA Virus Infections (1)
Appointments and Schedules (1) · Hepatitis B Vaccines (1) · Immunoglobulin G (1) · Ribavirin (1) · dasabuvir (1) · elbasvir-grazoprevir drug combination (1) · hepatitis C immune globulin, human (1) · ombitasvir (1) · paritaprevir (1)
AbbVie (2) · Biotest Pharmaceuticals Corporation (1) · Merck Sharp & Dohme LLC (1) · National Institute on Drug Abuse (NIDA) (1)
United States (2)
Emily Dumas, PhD (1) · Lu-Yu Hwang, MD (1) · Norah Terrault, MD, MPH (1) · Sarah Kopecky-Bromberg, PhD (1)
PMID 20936979, PMID 22075088, PMID 22170543, PMID 23152368, PMID 24631093, PMID 27720838, PMID 28193518, PMID 29404492, PMID 29461687
2014 (1), 2015 (1)